Recombinant
RabMAb

Recombinant Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)

Submit a review Submit a question References (6)

Overview

  • Product name

    Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free
    See all Apolipoprotein A I primary antibodies

  • Description

    Rabbit monoclonal [EP1368Y] to Apolipoprotein A I - Low endotoxin, Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: IHC-FoFr, IP, IHC-P, Flow Cyt, Sandwich ELISA, ICC/IF, WB, ELISAmore details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Synthetic peptide within Human Apolipoprotein A I aa 1-100 (N terminal). The exact sequence is proprietary.

  • Positive control

    • IHC-P: Human liver tissue ICC/IF: HepG2 cells FC: HepG2 cells IP: HepG2 cell lysates, human fetal liver tissue lysate

  • General notes

    ab185132 is a carrier-free antibody designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

    Our Low endotoxin, azide-free formats have low endotoxin level (≤ 1 EU/ml, determined by the LAL assay) and are free from azide, to achieve consistent experimental results in functional assays.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

Applications

Our Abpromise guarantee covers the use of ab185132 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-FoFr Use at an assay dependent concentration.
IP Use at an assay dependent concentration.
IHC-P Use at an assay dependent concentration. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

See IHC antigen retrieval protocols.
Flow Cyt Use at an assay dependent concentration.
Sandwich ELISA Use at an assay dependent concentration. Can be paired for Sandwich ELISA with Rabbit polyclonal to Apolipoprotein A I (ab33470).
ICC/IF Use at an assay dependent concentration.
WB Use at an assay dependent concentration. Predicted molecular weight: 30 kDa.
ELISA Use at an assay dependent concentration.

Target

  • Function

    Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.

  • Tissue specificity

    Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.

  • Involvement in disease

    Defects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
    Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
    Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed.
    Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.

  • Sequence similarities

    Belongs to the apolipoprotein A1/A4/E family.

  • Post-translational
    modifications

    Palmitoylated.
    Phosphorylation sites are present in the extracelllular medium.

  • Cellular localization

    Secreted.
  • Information by UniProt

  • Database links

    • Alternative names

      • Apo-AI antibody
      • ApoA I antibody
      • ApoA-I antibody
      • APOA1 antibody
      • APOA1_HUMAN antibody
      • Apolipoprotein A-I(1-242) antibody
      • Apolipoprotein A1 antibody
      • Apolipoprotein AI antibody
      • Apolipoprotein of high density lipoprotein antibody
      • ApolipoproteinAI antibody
      • Brp14 antibody
      • high density lipoprotein uptake antibody
      • Ltw1 antibody
      • Lvtw1 antibody
      • MGC117399 antibody
      • Sep1 antibody
      • Sep2 antibody
      see all

    Images

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)

      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human liver tissue sections labeling Apolipoprotein A I with purified ab52945 at 1/100 dilution (1.95 µg/ml). Perform heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab52945).

    • Immunocytochemistry/ Immunofluorescence - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)
      Immunocytochemistry/ Immunofluorescence - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)

      Immunocytochemistry/ Immunofluorescence analysis of HepG2 (Human hepatocellular carcinoma epithelial cell) cells labeling Apolipoprotein A I with purified ab52945 at 1/250 dilution (0.8 µg/ml). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at 1/200 (2.5 µg/ml) dilution. Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/1000 (2 µg/ml) dilution. DAPI (blue) was used as nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab52945).

    • Flow Cytometry - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)
      Flow Cytometry - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)

      Flow Cytometry analysis of HepG2 (Human hepatocellular carcinoma epithelial cell) cells labeling Apolipoprotein A I with purified ab52945 at 1/20 dilution (10 µg/ml) (red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab52945).

    • Immunoprecipitation - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)
      Immunoprecipitation - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)

      ab52945 (purified) at 1/20 dilution (1ug) immunoprecipitating Apolipoprotein A I in Human fetal liver lysates.
      Lane 1: Human fetal liver lysates 10ug
      Lane 2 (+): ab52945 & Human fetal liver lysates
      Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab52945 in Human fetal liver lysates
      For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/1000 dilution.
      Blocking and diluting buffer: 5% NFDM/TBST.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab52945).

    • ELISA - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)
      ELISA - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)

      Direct ELISA antigen dose-response curve using purified ab52945 at 0-1000ng/mL. Antigen (apo AI peptide) concentration of 1000ng/mL. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) (1/2500) was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab52945).

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)
      ab52945 at 1/100 dilution staining Apolipoprotein A I in human liver by Immunohistochemistry, Paraffin embedded tissue.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab52945).

    • Immunocytochemistry/ Immunofluorescence - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)
      Immunocytochemistry/ Immunofluorescence - Anti-Apolipoprotein A I antibody [EP1368Y] - Low endotoxin, Azide free (ab185132)
      ab52945 at 1/100 dilution staining Apolipoprotein A I in HEPG2 cells by Immunofluorescence.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab52945).

    References

    This product has been referenced in:

    • Lukkahatai N  et al. Proteomic Serum Profile of Fatigued Men Receiving Localized External Beam Radiation Therapy for Non-Metastatic Prostate Cancer. J Pain Symptom Manage N/A:N/A (2013). Read more (PubMed: 23916682) »
    • Nguyen SD  et al. Spontaneous remodeling of HDL particles at acidic pH enhances their capacity to induce cholesterol efflux from human macrophage foam cells. J Lipid Res 53:2115-25 (2012). Read more (PubMed: 22855736) »
    See all 6 Publications for this product

    Publishing research using ab185132? Please let us know so that we can cite the reference in this datasheet.

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab185132.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com